Navigation Links
Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:5/21/2013

PROMISE were fatigue (32 percent versus 42 percent), headache (32 percent versus 36 percent) and influenza-like illness (30 percent versus 20 percent), respectively. In addition, rash (19 percent versus 14 percent), itching (24 percent versus 17 percent), neutropenia (15 percent versus 17 percent), anemia (11 percent versus 6 percent), increased bilirubin (6 percent versus 2 percent), and photosensitivity conditions (4 percent versus none) were also observed. One patient in the simeprevir arm and no patients in the placebo arm discontinued treatment due to an adverse event.

Digestive Disease Week® (DDW®) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 18 – 21, 2013, at the Orange County Convention Center, Orlando, Florida. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.

About PROMISE
PROMISE is a global, Phase 3, randomized, double-blind, placebo-controlled clinical trial assessing the efficacy, safety and tolerability of simeprevir plus pegylated interferon and ribavirin versus pegylated interferon and ribavirin alone in adult patients with genotype 1 chronic hepatitis C with compensated liver disease, including all stages of liver fibrosis, who relapsed after previous interferon-based therapy.

In the PROMISE trial, 393 patients were randomized to receive one 150 mg capsule of simeprevir or placebo once dai
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
2. Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
3. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
4. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
5. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
6. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
7. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
8. GeneTex, Inc. to Launch a New Primary Antibody against HIF1a
9. Albireo Has Been Granted Orphan Drug Designation for A4250 from the US FDA for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and for Primary Biliary Cirrhosis (PBC)
10. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  eRelevance Corporation ( www.erelevancecorp.com ), ... that it has completed integration with Nextech, a ... Surgery and Dermatology practices. "Integration allows ... healthcare practices using Nextech," stated Bob Fabbio ... information from the EMR we are able to ...
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... Brazil and ... and commonly prescribe long-acting beta-agonist (LABA)- and long-acting ... so within current severe cost/coverage constraints. Therefore, new ... expected to launch in these countries—which will considerably ...
(Date:8/21/2014)... announces the list of stocks featured in the Analyst Blog. ... news and events impacting stocks and the financial markets. Stocks ... - Free Report ), IBM (NYSE: IBM - Free ... Report ), GlaxoSmithKline plc (NYSE: GSK - Free Report ... Report ). Today, Zacks is promoting its ,Buy, ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11
... , LAKE FOREST, Ill., Dec. 23 ... specialty pharmaceutical and medication delivery company, today announced that the ... Conference on Wednesday, Jan. 13, 2010, in San Francisco. , ... time on Wednesday, Jan. 13, 2010. It will be ...
... ... was marked by an abundance of media coverage and attention ... Hollywood. Over the past 12 months, several high-profile celebrities ... Lohan and, Courtney Love, while autopsies for Michael Jackson, Anna ...
Cached Medicine Technology:The Waismann Method Reflects on 2009: The Year of the Prescription Painkiller 2The Waismann Method Reflects on 2009: The Year of the Prescription Painkiller 3The Waismann Method Reflects on 2009: The Year of the Prescription Painkiller 4
(Date:8/22/2014)... autoimmune disease that affects 1 to 2 percent ... with pain, disability and joint disfigurements, but also ... and marital functioning. While many pharmacological advances help ... common. In addition, some patients avoid newer medications ... Because of this, there is interest in psychosocial ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... Dr. Sen and Dr. Samantha Pearson to help people ... and avoid corrective vision surgery by instead improving their ... prompting an investigative review. , “There’s a reason ... dollars in revenue each year—it’s because people just assume ...
(Date:8/22/2014)... 2014 Testosterone treatment lawsuits ( ... courts on behalf of men who allegedly suffered ... prescription low testosterone therapies, Bernstein Liebhard LLP reports. ... filed against Pfizer Inc. on July 31st by ... issues due to his use of Depo-Testosterone. (Case ...
(Date:8/22/2014)... 22, 2014 Mueller Sports Medicine is ... an exciting new product that provides non-drug instant relief ... active while you heal. The package includes 7 days ... new technology – it is not kinesiology tape. It’s ... PFTape™ System for Plantar Fasciitis is a breakthrough ...
(Date:8/22/2014)... 22, 2014 The improved access to ... in the developing world, has led to the decline ... of deaths due to AIDS globally. However, despite the ... of new patients becoming affected by the virus is ... undertaken by all related organisations and stakeholders, by 2015, ...
Breaking Medicine News(10 mins):Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3
... stop trial-and-error warfarin dosing , FRIDAY, Sept. 7 (HealthDay ... anti-clotting drug warfarin should make it easier to prescribe ... , Up to this point, doctors have had to ... left patients at risk of hemorrhaging from low doses ...
... Ability to Improve Patient Care, LYNWOOD, Calif., ... Center have reached a tentative agreement on a ... increase their ability to,advocate for improved patient care, ... qualified and skilled staff. The agreement, which ...
... Concentra ("Concentra" or the,"Company"), a leader in on-site ... at the construction site of the former World,Trade ... workers a,convenient way to treat work related injuries. ... site treat construction,personnel, building partners, and other individuals ...
... AdvaMed General Counsel,Christopher White issued the following statement ... Patent Reform Act of 2007:, "The closely ... the significant bipartisan opposition to the patent reform,plan ... by,making patents easier to challenge and cheaper to ...
... Zimmer,Holdings, Inc. (NYSE: ZMH ; SWX: ZMH), ... (TSX-Venture: OSH), a leader in computer,navigation for orthopaedic ... Acquisition Co., has mailed today its offer and,circular ... takeover bid for all of ORTHOsoft,s outstanding common ...
... 650,000 hospital visits, U.S. study finds , FRIDAY, Sept. 7 (HealthDay ... both the little one and his or her family from getting ... U.S. children between six months and five years old got their ... visits due to flu could be prevented. , "We found that ...
Cached Medicine News:Health News:Researchers Find Better Way to Deliver Blood Thinner 2Health News:Workers Win Contract at St. Francis Medical Center 2Health News:Concentra Opens On-Site Medical Unit at World Trade Center Site 2Health News:Zimmer Holdings Offer and ORTHOsoft Directors' Circular Mailed to Shareholders 2Health News:Zimmer Holdings Offer and ORTHOsoft Directors' Circular Mailed to Shareholders 3Health News:Zimmer Holdings Offer and ORTHOsoft Directors' Circular Mailed to Shareholders 4Health News:Child's Flu Shot Helps Whole Family 2
Transcranial Doppler dedicated to intensive care unit and operating theatre....
The Spencer Technologies PMD 100 (TCD 100M) is the worlds first stand-alone digital transcranial doppler system....
Flagship Transcranial Doppler system with multiple channel options, multi-depth options....
The portable, cost-effective system designed for fast studies and bedside reporting. The size, features and cost make this a perfect unit for a new practice, or as a second or third unit for larger h...
Medicine Products: